Neupro
PreclinicalSmall molecule
UCBNeupro is one of 82 small molecule programs targeting Restless Legs Syndrome. It is currently in Preclinical.
2
Indications
6
Total Trials
1
Active Trials
81
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
165 competitors in Parkinson Disease
#DrugCompanyPhaseTrials
1Vesicare
AstellasPhase 3
Byetta
AstraZenecaPhase 3
Mirapex
Boehringer IngelheimPhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Allegra
CChattem
Phase 3
Xifaxan
SSalix
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Wakix
HHarmony Biosciences Management, Inc.
Phase 3
XEOMIN
MMerz Pharmaceuticals GmbH
Phase 3
Levodopa/carbidopa
Orion Corporation, Orion PharmaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment1 trial
Parkinson's Disease1 trial
Restless Legs Syndrome1 trial
Single Dose1 trial
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Neupro. EMBL-EBI & Wellcome Sanger Institute.
- [4]